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Abstract
Background: Hyperphosphataemia is linked to cardiovascular disease and mortality in chronic kidney disease
(CKD). Outcome in CKD is also affected by socioeconomic status. The objective of this study was to assess the
associations between serum phosphate, multiple deprivation and outcome in CKD patients.
Methods: All adult patients currently not on renal replacement therapy (RRT), with first time attendance to the
renal outpatient clinics in the Glasgow area between July 2010 and June 2014, were included in this prospective
study. Area socioeconomic status was assessed as quintiles of the Scottish Index of Multiple Deprivation (SIMD).
Outcomes were all-cause and cardiovascular mortality and commencement of RRT.
Results: The cohort included 2950 patients with a median (interquartile range) age 67.6 (53.6–76.9) years. Median
(interquartile range) eGFR was 38.1 (26.3–63.5) ml/min/1.73 m2, mean (±standard deviation) phosphate was 1.13
(±0.24) mmol/L and 31.6 % belonged to the most deprived quintile (SIMD quintile I). During follow-up 375 patients
died and 98 commenced RRT. Phosphate ≥1.50 mmol/L was associated with all-cause (hazard ratio (HR) 2.51; 95 %
confidence interval (CI) 1.63-3.89) and cardiovascular (HR 5.05; 95 % CI 1.90–13.46) mortality when compared to
phosphate 0.90–1.09 mmol/L in multivariable analyses. SIMD quintile I was independently associated with all-cause
mortality. Phosphate did not weaken the association between deprivation index and mortality, and there was no
interaction between phosphate and SIMD quintiles. Neither phosphate nor SIMD predicted commencement of RRT.
Conclusions: Multiple deprivation and serum phosphate were strong, independent predictors of all-cause mortality
in CKD and showed no interaction. Phosphate also predicted cardiovascular mortality. The results suggest that
phosphate lowering should be pursued regardless of socioeconomic status.
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Background
Disorders of mineral metabolism, in particular hyper-
phosphataemia, are linked to cardiovascular morbidity
and mortality in chronic kidney disease (CKD) [1]. In-
dependent associations between serum phosphate and
cardiovascular and all-cause mortality have been shown
among persons on chronic dialysis [2, 3] and in non-
dialysis CKD patients [4–6]. The proposed mechanisms
for this association involve endothelial dysfunction [7] and
vascular calcification [8–10].
The burden of CKD differs substantially across socio-
economic groups, with higher CKD incidence and preva-
lence rates in lower compared to higher socioeconomic
groups [11–16]. Moreover, the risk of adverse outcome
in CKD, such as CKD progression [17, 18] and mortality
[19, 20], is increased in patients with lower socioeconomic
status. These associations are only partly explained by the
high rates of traditional cardiovascular and renal risk fac-
tors observed in these groups [21–23]. Factors characteris-
ing deprivation and thus having an unfavourable impact
on health outcome [24] may vary between geographical
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regions, and these associations should be examined in
various areas.
Serum phosphate has been shown to increase with de-
creasing socioeconomic status independent of estimated
glomerular filtration rate (eGFR) in the general popula-
tion [25] and in CKD patients [26]. Dietary differences
with a high intake of processed food (“fast food”) contain-
ing easily absorbable phosphorus additives in deprived
groups may explain this association [27, 28].
It is not known whether the higher phosphate level
partially can explain the association between low socio-
economic status and adverse outcome in CKD.
The objective of the present prospective study was to
assess the associations between serum phosphate, mul-
tiple deprivation and CKD outcome in a Scottish cohort
of CKD patients not requiring renal replacement therapy
(RRT) at baseline. Specifically, we wanted to address
whether hyperphosphataemia partly could explain a
more adverse outcome among patients with low socio-
economic status.
Subjects and Methods
Study population
The Glasgow Renal and Transplant Unit serves a popu-
lation of 1.5 million people across West and Central
Scotland. All adult patients attending the outpatient
clinics for the first time between 1st July 2010 and 30th
June 2014 were identified through the Strathclyde Elec-
tronic Renal Patient Record (Vitalpulse, UK) (n = 3676).
Patients with previous kidney transplants or on chronic
dialysis (n = 170) were excluded. Also, patients with
missing serum phosphate values (n = 556) were excluded
from the present study. Use of anonymised data from
this database has been approved by the West of Scotland
Ethics Committee for use of NHS Greater Glasgow and
Clyde ‘Safe Haven’ data for research.
Measurements
For each patient, demographic and clinical data were re-
corded on their first attendance to the outpatient clinic.
Previous cardiovascular disease and known diabetes
were assessed from baseline data recorded in the elec-
tronic patient record, derived from the General Practi-
tioner records for each patient. Laboratory data were
acquired from the local hospital laboratories. Height and
weight were measured and blood pressure was recorded
by the nurses at each location. Due to a large number of
missing values for height, we applied body weight (in kg)
instead of body mass index as a measure of obesity in
the multivariable analyses. Creatinine based eGFR was
calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [29].
Socioeconomic status for each patient was obtained
using the Scottish Index of multiple Deprivation (SIMD)
system. SIMD is the Scottish Government’s widely
accepted tool for identifying areas suffering from
deprivation [30]. Scotland is divided into 6505 so-called
datazones, each datazone including an average of 800
persons. SIMD combines 38 indicators across 7 domains
(employment, income, health, education, geographic ac-
cess to service, crime and housing), and each domain is
weighted according to its importance to the overall con-
cept of multiple deprivation [30, 31]. The SIMD for all
datazones are ranked from 1 (most deprived) to 6505
(least deprived), resulting in a relative measure of area
deprivation. The SIMD rank for each patient was ac-
quired by linking the patient’s postcode to a SIMD data-
zone. In the present paper, SIMD quintiles recorded
from the central SIMD database were applied. Quintile I
comprise persons living in the most deprived areas.
Outcomes
Date of death was received from the electronic patient
record which is cross referenced with the General Regis-
ter for Scotland. Cause of death was determined from
death certificates if available in the patient record, or ad-
judicated by the authors when the electronic patient rec-
ord contained information about the final course leading
to death. A death was assigned a cardiovascular cause if
the patient died from any cardiac disease, stroke or per-
ipheral vascular disease. Date of commencing RRT was
retrieved from the electronic patient record. When
assessing cardiovascular mortality and RRT commence-
ment, patients were censored on the date of death if they
did not reach the end-point of interest, but died from
other or unknown cause. Follow-up time was assigned
from the first renal clinic attendance date to the date of
death or 3rd October 2014 for all-cause and cardiovascu-
lar mortality, and to the date of commencing RRT, the
date of death or 3rd October 2014, whichever came first,
for the RRT endpoint.
Statistical analyses
Data are presented as mean (±standard deviation [SD]),
median (interquartile range) or number (percentage) as
appropriate. Serum phosphate was categorised into five
groups: <0.90 mmol/L, 0.90-1.09 mmol/L, 1.10–1.29
mmol/L, 1.30–1.49 mmol/L and ≥1.50 mmol/L. Differ-
ences in baseline characteristics across these phosphate
categories were assessed using one-way ANOVA,
Kruskall-Wallis test and Jonckheere-Terpstra trend test
and Chi square test as appropriate, and P for linear
trend was reported. Similarly, differences in characteris-
tics across SIMD quintile groups were examined. In
these analyses, SIMD quintiles II and III were merged
into one group, as were quintiles IV and V.
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We used multivariable linear regression analysis to as-
sess the cross-sectional association between phosphate
and other variables.
Crude incidence rates were calculated as number of
events per 1000 person years at risk. Differences in inci-
dence rates across the phosphate categories were tested
for by a normal test with continuity correction. Because
a trend towards a J-formed association between phos-
phate and all-cause mortality was observed in multivari-
able adjusted analyses, the phosphate range 0.90–1.09
mmol/L was set as reference.
Cox proportional hazard regression analyses were used
to examine the associations between phosphate, SIMD
quintiles and the three endpoints. Covariates were en-
tered block wise. The SIMD quintiles and phosphate cat-
egories, respectively, were adjusted for sex, age and
eGFR in two separate models, Model 1a and 1b. In
Model 2, SIMD quintiles, phosphate categories, age sex
and eGFR were entered into the same model. Model 3
tested the addition of traditional cardiovascular risk fac-
tors (systolic and diastolic blood pressure, body weight,
presence/absence of diabetes and/or coronary heart dis-
ease) to Model 2, and in Model 4, urinary protein-
creatinine ratio (PCR), serum albumin and haemoglobin
were added. Relevant interactions, including interaction
between the SIMD quintiles and phosphate for the pre-
diction of each endpoint, were tested for. In separate
Cox regression analyses, the cohort was classified into
four groups according to their combination of phosphate
(≥1.50 mmol/L vs. all others) and SIMD quintile (quintile
I vs. all others). The association with all-cause mortality
was assessed, including the same covariates as in Model 4
described above. The proportional hazard assumption was
checked by visual inspection of the –log-log curves. P
values <0.05 were considered significant. Analyses were
run using IBM SPSS Statistics software version 22 (IBM
Corp., Armonk, NY).
Results
Baseline characteristics
The 556 patients who had missing phosphate measure-
ments and therefore were excluded from the study, were
significantly younger, had lower PCR and less frequently
diabetes than the 2950 patients (1475 men and 1475
women) who comprised the study cohort. However, the
556 excluded patients did not differ significantly with
regards to other properties including distribution of
CKD stages and SIMD quintiles (P for differences be-
tween the groups =0.14 and 0.77, respectively). During
follow-up, 76 (13.7 %) of patients with missing phos-
phate measurements died; this was not significantly dif-
ferent from the death rate in the study cohort (12.7 %; P
for between-group difference =0.54). The study cohort
had median age 67.6 (53.6–76.9) years, median eGFR
38.1 (26.3–63.6) ml/min/1.73 m2, mean phosphate 1.13
(±0.24) mmol/L, and 929 (31.6 %) were categorised into
the most deprived quintile (SIMD quintile I). CKD
stages were distributed as follows: 797 (26.9 %) had stage
1 or 2, 1161 (39.4 %) had stage 3, 846 (28.7 %) stage 4
and 147 patients (5.0 %) had stage 5 CKD. Fifty-two
(1.8 %) persons attended for live donor assessment.
Baseline characteristics were assessed according to the
phosphate categories. Compared to the category with
phosphate 0.90–1.09 mmol/L (n = 912), the high phos-
phate category (phosphate ≥1.50 mmol/L; n = 177) was
characterised by more women (58.2 % vs. 44.8 %) and a
higher percentage of persons residing in the lowest
SIMD quintile areas (33.3 % vs. 30.9 %). As expected,
eGFR was lower in the high phosphate category. There
was no consistent trend towards a worse cardiovascular
risk profile in the high versus low phosphate category.
Characteristics were compared across the SIMD quin-
tile groups (Table 1). Age was lower and the percentage
of women higher in the most deprived compared to the
least deprived quintiles. Phosphate was significantly
higher in SIMD quintile I than in quintiles IV and V,
whereas eGFR did not differ significantly across the
SIMD quintiles. Diabetes was more frequent in the most
deprived quintile, whereas coronary heart disease was
evenly distributed across the SIMD quintiles.
Predictors of serum phosphate
Table 2 displays the variables that were independently
associated with serum phosphate. In addition to socio-
economic deprivation, lower age, eGFR and body weight,
increasing urinary PCR and female sex were among the
predictors of increasing phosphate.
Serum phosphate, deprivation and outcomes
Median follow-up time was 1.71 (0.93–2.79) years for
all-cause and cardiovascular mortality, and 1.66 (0.89–2.74)
years for RRT commencement. During follow-up, 375 of
the patient died. The cause of death was determined in 254
(67.7 %) cases, and among these, 67 patients (26.3 %) died
from cardiovascular disease. Ninety eight patients started
RRT (80 started in-centre haemodialysis, 12 started
peritoneal dialysis and 7 received a kidney transplant
pre-emptively).
Crude all-cause mortality rates and incidence rates of
RRT initiation increased with increasing phosphate
(Table 3A-C). The number of cardiovascular deaths was
low in each phosphate category, and the lowest inci-
dence rate was found among patients with phosphate
1.30–1.49 mmol/L. The crude all-cause and cardiovascu-
lar mortality rates increased with increasing deprivation.
Also, the crude incidence rate for RRT was highest in
the most deprived quintile (data not shown).
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When age, sex and eGFR were adjusted for, the all-
cause mortality risk was increased by 275 % (hazard ra-
tio [HR] 2.75; 95 % confidence interval [CI] 1.89–4.00)
in the highest phosphate category compared to refer-
ence. Similarly, residing in the two lower SIMD quintile
areas implied an elevated risk of death of 63 and 69 %,
respectively (Table 4, Model 1a and 1b). The estimates
for both the SIMD quintiles and phosphate categories
were essentially unchanged when these variables were
entered into the same model (Model 2). Adding trad-
itional cardiovascular risk factors to the model slightly
weakened the association between deprivation and mor-
tality, but not between phosphate and mortality. How-
ever, by including the covariates urinary PCR, serum
albumin and haemoglobin, the association between
phosphate and mortality also was weakened. In the multi-
variable adjusted analyses (Model 4) there was a border-
line significant association between the lowest phosphate
category (<0.90 mmol/L) and all-cause mortality.
A strong association was found between phosphate ≥1.50
mmol/L and cardiovascular mortality (Table 5), and the as-
sociation was not substantially altered by adding SIMD
quintiles, traditional and non-traditional risk factors to the
Cox model. Deprivation was not a significant predictor of
cardiovascular mortality.
SIMD quintiles were not associated with RRT initi-
ation in adjusted analyses. High phosphate was associ-
ated with commencement of RRT in analyses adjusted
Table 1 Baseline characteristics according to Scottish Index of Multiple Deprivation (SIMD) quintiles 2012
SIMD quintile I (n = 929) SIMD quintile II–III (n = 1096) SIMD quintile IV–V (n = 912) P for linear trend
Men, n (%) 443 (47.7) 538 (49.1) 486 (53.3) 0.016
Age, years 66.3 (51.0–76.2) 68.2 (54.5–77.4) 68.2 (54.6–77.3) 0.016
Phosphate, mmol/L 1.15 ±0.24 1.15 ±0.25 1.11 ±0.24 0.001
Phosphate >1.30 mmol/L 207 (22.3) 237 (21.6) 165 (18.1) 0.002
eGFR, mL/min/1.73 m2 39.9 (27.3–67.8) 36.0 (25.5–59.0) 39.3 (27.0–63.7) 0.7
Urinary protein-creatinine ratio, mg/mmol 32.6 (7.6–137.8) 37.0 (9.2–130.1) 25.0 (5.6–102.6) 0.041
Albumin, g/L 36.2 ±5.7 37.3 ±5.8 37.5 ±5.8 <0.001
Haemoglobin, g/L 123.3 ±21.4 123.4 ±20.7 124.9 ±20.3 0.11
Systolic blood pressure, mm Hg 145.9 ±25.1 148.5 ±26.1 148.5 ±25.8 0.035
Diastolic blood pressure, mm Hg 77.9 ±13.0 77.7 ±13.4 78.3 ±12.9 0.48
Body weight, kg 80.7 ±21.4 80.8 ±19.8 80.0 ±19.4 0.46
Body mass index, kg/m2 30.0 ±7.3 29.6 ±6.3 28.6 ±6.4 <0.001
Diabetes, n (%) 301 (32.4) 352 (32.1) 229 (25.1) 0.001
Coronary heart disease, n (%) 162 (17.4) 196 (17.9) 143 (15.7) 0.32
Values are given as mean ± SD, median (interquartile range) or number (percentage) as appropriate. eGFR Estimated glomerular filtration rate according to the
CKD-EPI equation, SIMD Scottish index of multiple deprivation. Quintile I comprise the most deprived and quintile V the least deprived
Table 2 Predictors of serum phosphate (mmol/L) at baseline in multivariable linear regression
β coefficient 95 % confidence interval Standardised β coefficient P value
Sex, male −0.35 (−0.53 - -0.17) −0.077 <0.001
Age, per year −0.003 (−0.003 - -0.002) −0.207 <0.001
eGFR, per ml/min/1.73 m2 −0.001 (−0.002 - -0.001) −0.177 <0.001
SIMD quintiles I Ref.
II–III −0.011 (−0.003 - 0.010) −0.021 0.31
IV–V −0.029 (−0.049 - -0.009) −0.058 0.005
Diastolic blood pressure, per mm Hg -0.001 (-0.002 - 0.000) -0.047 0.053
Body weight, per kg −0.001 (−0.002 - -0.001) −0.111 <0.001
Urinary PCR, per 10 mg/mmol 0.00078 (0.00050 - 0.00107) 0.113 <0.001
Haemoglobin, per g/L −0.002 (−0.003 - -0.001) −0.174 <0.001
Potassium, per mmol/L 0.073 (0.057 - 0.090) 0.173 <0.001
Adjusted R2 0.172
eGFR Estimated glomerular filtration rate, SIMD Scottish index of multiple deprivation. Quintile I comprise the most deprived. PCR Protein-creatinine ratio. Also
adjusted for systolic blood pressure, albumin adjusted serum calcium, serum albumin, presence/absence of diabetes and/or coronary heart disease
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for age, sex, eGFR, deprivation and traditional cardiovas-
cular risk factors, but no significant association
remained after adjustment for urinary PCR, serum albu-
min and haemoglobin (Table 6).
As a continuous variable serum phosphate was associ-
ated with all-cause mortality when adjusted for age, sex,
eGFR, SIMD quintiles and traditional cardiovascular risk
factors (HR 2.56; 95 % CI 1.72–3.81; P < 0.001 per
mmol/L increase), but the significant association disap-
peared with adjustment for urinary PCR, serum albumin
and haemoglobin. Similar relationships were seen be-
tween serum phosphate and the two other endpoints
(data not shown).
There was no significant interaction between serum
phosphate and the SIMD quintiles for the prediction of
any endpoint. Nor was there any significant interaction
between sex and phosphate or between eGFR and
phosphate.
Figure 1 displays HR (95 % CI) for all-cause mortality
when the cohort was classified by the combination of
phosphate level and SIMD quintiles, and Fig. 2 shows
the corresponding adjusted survival curves. Phosphate
≥1.50 mmol/L was a predictor of death irrespective of
SIMD quintile, and the most deprived SIMD quintile
was only borderline significantly associated with mortal-
ity in this model.
Discussion
In this large cohort of CKD patients not established on
RRT, we found that higher phosphate was an independ-
ent predictor of all-cause and cardiovascular mortality.
Multiple deprivation, measured as SIMD quintiles, was
also independently associated with all-cause mortality.
Serum phosphate was significantly higher in patients
from the most deprived compared to the least deprived
areas, but the association between phosphate and mor-
tality was not altered by deprivation, and there was no
interaction between these two variables for the predic-
tion of any endpoint. Therefore, the higher phosphate
level observed in patients from the most deprived areas
Table 3 Crude incident rates (number of events per 1000 patient years of risk) for all-cause mortality, cardiovascular mortality and
commencement of renal replacement therapy according to baseline phosphate categories
A. All-cause mortality
Phosphate categories Number of patients
at risk
Number of events Follow-up time (months) Crude incidence rate 95 % confidence interval P value*
<0.90 mmol/L 422 39 18.89 (10.94–32.46) 50.82 (34.87–66.77) <0.001
0.90–1.09 mmol/L 912 96 21.90 (11.47–33.66) 54.38 (43.50–65.26) Ref.
1.10–1.29 mmol/L 1004 130 21.68 (11.37–34.29) 67.48 (55.88–79.08) <0.001
1.30–1.49 mmol/L 435 64 20.30 (11.63–32.23) 78.90 (59.57–98.23) <0.001
≥1.50 mmol/L 177 46 17.58 (6.85–32.00) 154.94 (110.17–199.72) <0.001
Total 2950 375 20.57 (11.14–33.48) 67.36 (60.54–74.18)
B. Cardiovascular mortality
Phosphate categories Number of Patients
at risk
Number of Events Follow-up time (months) Crude Incidence Rate 95 % Confidence Interval P value*
<0.90 mmol/L 422 6 18.89 (10.94–32.46) 7.82 (1.56–14.07) 0.003
0.90–1.09 mmol/L 912 18 21.90 (11.47–33.66) 10.20 (5.49–14.91) Ref.
1.10–1.29 mmol/L 1004 24 21.68 (11.37–34.29) 12.46 (7.47–17.44) 0.037
1.30–1.49 mmol/L 435 6 20.30 (11.63–32.23) 7.40 (1.48–13.32) <0.001
≥1.50 mmol/L 177 13 17.58 (6.85–32.00) 43.79 (19.98–67.59) <0.001
Total 2950 67 20.57 (11.14–33.48) 12.03 (9.15–14.92)
C. Renal Replacement Therapy
Phosphate categories Number of Patients
at risk
Number of Events Follow-up time (months) Crude Incidence Rate 95 % Confidence Interval P value*
<0.90 mmol/L 422 4 18.79 (10.93–32.36) 5.24 (0.10–10.38) <0.001
0.90–1.09 mmol/L 912 14 21.65 (11.18–33.63) 8.00 (3.81–12.18) Ref.
1.10–1.29 mmol/L 1004 21 20.91 (11.07–33.64) 11.05 (6.32–15.78) 0.004
1.30–1.49 mmol/L 435 26 19.42 (11.07–31.27) 33.26 (20.48–46.05) <0.001
≥1.50 mmol/L 177 33 13.63 (4.78–28.09) 133.96 (88.25–179.67) <0.001
Total 2950 98 19.88 (10.68–32.92) 18.01 (14.44–21.75)
*P value for comparison with the reference group. Follow-up time is given as median (interquartile range)
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could not explain the increased mortality risk in the
deprived group. Nor could the increased mortality risk
implied by higher phosphate be explained in terms of so-
cioeconomic deprivation. These associations have never
previously been demonstrated in a cohort of CKD patients.
Our data support previous findings of a relationship
between slightly increased phosphate and increased risk
of all-cause [1, 4–6, 32] and cardiovascular [1, 5, 6] mor-
tality in non-RRT CKD patients.
It has long been recognised that CKD incidence and
outcome vary between patients from different socioeco-
nomic groups [12, 17, 18, 20, 23], but the reasons for
this variation have not been fully explained [24]. Genetic
and other biological aspects, differences in life style,
health related behaviour and environmental hazards, and
inequalities in health services may be involved. The in-
fluence of each factor is believed to differ from one area
to another [12]. In a study involving the same Scottish
population, a higher incidence of biopsy-proven kidney
disease, particularly IgA nephropathy, was observed
among patients from areas with lower SIMD ranks com-
pared to patients living in less deprived areas [33].
Consistent with this, a large proportion of the patients
in our cohort, 31.6 %, resided in areas ranked in the low-
est SIMD quintile.
Individual and area-level socioeconomic disadvantage
increase the risk of consuming a disproportionally large
amount of inexpensive, unhealthy “fast food” [34, 35]. In
addition to their high content of fat, energy and salt, a
recent concern regarding processed foods is their high
content of easily absorbable inorganic phosphate addi-
tives [27]. An association between estimated consump-
tion of phosphate and all-cause and cardiovascular
mortality was demonstrated in a sample of healthy US
adults with normal eGFR [36]. Persons who consumed
high amounts of phosphate were younger, more physic-
ally active, better educated and less often classified as
poor than the quartile with the lowest phosphate intake.
However, the authors discuss the possibility that phos-
phorus intake may have been systematically underesti-
mated from nutrient databases not updated on phosphate
additives in processed foods [36]. In the present study,
serum phosphate was significantly higher in SIMD quin-
tile I than in quintiles IV and V. The groups had similar
Table 4 Hazard ratios (HR) and 95 % confidence intervals (CI) for all‐cause mortality. Predictors are baseline variables
Model 1a and b Model 2 Model 3 Model 4
HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value
SIMD quintiles V Ref. Ref. Ref. Ref.
IV 1.28 0.86–1.91 0.22 1.33 0.89–1.99 0.16 1.28 0.85–1.92 0.23 1.46 0.94–2.26 0.09
III 1.31 0.87–1.96 0.19 1.26 0.84–1.89 0.26 1.22 0.81–1.83 0.34 1.19 0.75–1.87 0.46
II 1.63 1.13–2.35 0.009 1.60 1.11–2.30 0.012 1.50 1.03–2.17 0.033 1.56 1.04–2.34 0.031
I 1.69 1.19–2.40 0.003 1.68 11.18–2.38 0.004 1.55 1.09–2.21 0.015 1.60 1.10–2.34 0.015
Phosphate groups <0.90 mmol/L 1.08 0.74–1.57 0.70 1.09 0.75–1.58 0.67 1.12 0.76–1.64 0.57 1.44 0.97–2.15 0.073
0.90–1.09 mmol/L Ref. Ref. Ref. Ref.
1.10–1.29 mmol/L 1.24 0.95–1.62 0.12 1.22 0.93–1.59 0.15 1.24 0.95–1.63 0.12 1.20 0.89–1.62 0.24
1.30–1.49 mmol/L 1.39 1.01–1.93 0.045 1.38 0.99–1.92 0.05 1.38 0.98–1.93 0.06 1.03 0.70–1.51 0.88
≥1.50 mmol/L 2.75 1.89–4.00 <0.001 2.73 1.88–3.99 <0.001 2.86 1.93–4.24 <0.001 2.51 1.63–3.89 <0.001
Table 5 Hazard ratios (HR) and 95 % confidence intervals (CI) for cardiovascular mortality. Predictors are baseline variables
Model 1a and b Model 2 Model 3 Model 4
HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value
SIMD quintiles V Ref. Ref. Ref. Ref.
IV 0.58 0.21-1.61 0.30 0.65 0.23-1.79 0.40 0.65 0.23-1.80 0.41 0.55 0.17-1.81 0.33
III 0.93 0.38-2.30 0.88 0.87 0.35-2.16 0.77 0.90 0.36-2.22 0.81 0.69 0.24-1.98 0.49
II 1.04 0.46-2.35 0.93 1.01 0.45-2.30 0.97 0.96 0.42-2.22 0.93 0.95 0.39-2.35 0.92
I 1.65 0.80-3.40 0.18 1.65 0.80-3.42 0.18 1.38 0.66-2.90 0.39 1.43 0.66-3.11 0.37
Phosphate groups <0.90 mmol/L 0.90 0.36-2.28 0.83 0.89 0.35-2.26 0.81 1.11 0.43-2.87 0.83 1.48 0.56-3.94 0.44
0.90–1.09 mmol/L Ref. Ref. Ref. Ref.
1.10–1.29mmol/L 1.25 0.67–2.32 0.48 1.24 0.67–2.30 0.50 1.50 0.79–2.84 0.22 1.63 0.80–3.31 0.18
1.30–1.49mmol/L 0.76 0.29–1.94 0.56 0.75 0.29–1.93 0.55 0.97 0.37–2.53 0.95 0.84 0.29–2.44 0.75
≥1.50 mmol/L 4.75 2.16–10.44 <0.001 4.55 2.07–10.03 <0.001 6.18 2.61–14.65 <0.001 5.05 1.90–13.46 0.001
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Table 6 Hazard ratios (HR) and 95 % confidence intervals (CI) for renal replacement therapy. Predictors are baseline variables
Model 1a and b Model 2 Model 3 Model 4
HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value
SIMD quintiles V Ref. Ref. Ref. Ref.
IV 1.03 0.51-2.05 0.94 1.04 0.52–2.09 0.90 1.02 0.51–2.06 0.95 1.47 0.68–3.19 0.33
III 0.81 0.38-1.70 0.58 0.83 0.39–1.75 0.62 0.84 0.40–1.79 0.66 1.03 0.45–2.37 0.94
II 0.44 0.21-0.95 0.037 0.43 0.20–0.93 0.032 0.47 0.22–1.00 0.051 0.47 0.20–1.12 0.087
I 1.16 0.63-2.10 0.64 1.18 0.65–2.16 0.59 1.12 0.60–20.08 0.73 1.01 0.51–2.01 0.98
Phosphate groups <0.90 mmol/L 0.77 0.25–2.34 0.64 0.82 0.27–2.52 0.73 1.02 0.33–3.16 0.97 0.95 0.26–3.46 0.94
0.90–1.09 mmol/L Ref. Ref. Ref. Ref.
1.10–1.29 mmol/L 1.16 0.58–2.29 0.68 1.22 0.61–2.41 0.57 1.37 0.68–2.75 0.38 1.13 0.53–2.43 0.76
1.30–1.49 mmol/L 1.83 0.94–3.58 0.077 1.76 0.90–3.46 0.098 2.12 1.06–4.24 0.034 1.53 0.72–3.27 0.76
≥1.50 mmol/L 2.29 1.12–4.71 0.024 2.51 1.24–5.10 0.011 3.03 1.43-6.42 0.004 1.64 0.71-3.82 0.25
eGFR, Estimated glomerular filtration rate according to the CKD‐EPI equation, SIMD Scottish index of multiple deprivation. Quintile I comprise the most deprived
and quintile V the least deprived. PCR Protein‐creatinine ratio, Model 1a SIMD quintiles, eGFR Age and sex, Model 1b Phosphate groups, eGFR Age and sex, Model 2
SIMD quintiles, phosphate groups, eGFR Age and sex, Model 3 Model 2 plus traditional cardiovascular risk factors (presence of diabetes and/or coronary heart
disease, systolic and diastolic blood pressure, body weight), Model 4 Model 3 plus non‐traditional risk factors (urinary PCR, serum albumin, haemoglobin)
Fig. 1 Multivariable adjusted hazard ratios (95 % confidence intervals) for all-cause mortality by categorisation of serum phosphate (<1.50 mmol/L
or ≥1.50 mmol/L) and quintiles of Scottish Index of multiple Deprivation (SIMD) at baseline. SIMD quintile 1 comprises the most deprived
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eGFR, and it is reasonable to believe that differences in
phosphate intake caused the difference in serum phos-
phate observed between these groups. Other possible ex-
planations for the higher phosphate relate to the variables
found to be independently associated with phosphate
(Table 2) and also overrepresented in the most deprived
group, including female sex, lower age and higher urinary
PCR. However, the lack of interaction between serum
phosphate and deprivation in our study does not support
a differential effect of phosphate on clinical events accord-
ing to socioeconomic status, and restriction of phosphate
intake should be pursued in CKD patients regardless of
socioeconomic status.
The high prevalence of traditional risk factors, such as
hypertension, diabetes [21, 37], smoking [22], lack of
physical activity [23] and abdominal obesity [23, 38] in
lower socioeconomic status groups, partly explains the
association between deprivation and adverse outcome in
CKD. In our cohort, the patients residing in deprived
areas had slightly higher body mass index and the high-
est prevalence of diabetes. Also, urinary PCR was higher
in the lowest SIMD quintile. However, other traditional
cardiovascular risk factors were not associated with the
lower SIMD quintile. Moreover, low SIMD rank remained
an independent significant predictor of mortality, and
other explanations should be sought. Unfortunately,
information about smoking habits, possibly an important
confounder, was not available in our database.
Although phosphate was an independent predictor of
RRT commencement when adjusted for eGFR and car-
diovascular risk factors, the association did not remain
significant when other markers of uraemia including
serum albumin were added to the statistical model. An
association between serum phosphate and eGFR decline
in advanced [39] and earlier [40] stages of CKD has been
reported, and increased phosphate has been implicated
as a predictor of kidney failure defined as the need for
RRT [41, 42]. The discrepancy between these previous
reports and the lack of association observed in the
present study may be explained in terms of differences
in cohorts, observation time and covariate adjustment.
Moreover, timing of RRT is a decision based upon
Fig. 2 Multivariable adjusted cumulative survival by categorisation of serum phosphate (<1.50 mmol/L or ≥1.50 mmol/L) and quintiles of Scottish
Index of multiple Deprivation (SIMD) at baseline. SIMD quintile 1 comprises the most deprived
Solbu et al. BMC Nephrology  (2015) 16:194 Page 8 of 10
evaluation of several laboratory values and symptoms,
and practice patterns vary around the world [43]. Mul-
tiple deprivation was not independently associated with
RRT commencement in the present study.
Our study had several strengths and limitations. The
large cohort size and the completeness of all-cause mor-
tality and RRT commencement registration were obvious
strengths. The SIMD classification system is a validated,
robust indicator of deprivation at area level. In this
study, the index was used as a proxy for individual
deprivation. However, there may be deprived individuals
living in less deprived areas and vice versa. Moreover,
the SIMD measures deprivation on a relative scale within
the country, and direct comparison with deprivation in
other countries is not possible.
The cause of death could not be determined in one
third of the deaths in this study. Therefore, the analyses
involving cardiovascular mortality should be interpreted
with caution. According to existing data [44], a higher
proportion should be expected to die from a cardiovas-
cular cause than the 26.3 % (of the classified death cases)
observed in the present study. Many of the unclassified
death events in our study were out-of-hospital deaths,
probably not infrequently sudden cardiac deaths.
Important covariates were lacking. Tobacco use is a
strong predictor of cardiovascular and all-cause mortal-
ity [45]. To our knowledge, there is no data suggesting
that smoking confound the association between phos-
phate and outcome, but the association between area
deprivation and mortality may have been weakened with
adjustment for tobacco use. We also lacked information
about use of medication, including antihypertensive
drugs, phosphate binders and active vitamin D.
Conclusions
In summary, we have demonstrated that serum phosphate
and area multiple deprivation index were independent
predictors of all-cause mortality in a large Scottish cohort
of first time attendants to an outpatient renal clinic. The
results support similar findings in previous studies. How-
ever, despite a higher serum phosphate in the most de-
prived, deprivation index did not alter the association
between phosphate and mortality and vice versa, and
there was no interaction between deprivation index and
phosphate. Our data support a strategy aimed at lowering
serum phosphate in all CKD patients, regardless of socio-
economic status.
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